Rifaximine versus neomycin in the treatment of portosystemic encephalopathy.

Abstract

In 14 patients with cirrhosis and chronic portosystemic encephalopathy, the effectiveness of treatment with a new non-assorbable antibiotic (rifaximine) was compared to neomycin. The parameters evaluated were: bradylalia, flapping tremor, performance, visual evoked potentials and the trial making test. Both treatments were combined with lactulose. The analysis of results showed a rate of positive results in the patients treated with rifaximine greater than that with neomycin. Differences, however, were not significant.

• Authors: S Di Piazza, M Gabriella Filippazzo, L M Valenza, S Morello, L Pastore, A Conti, S Cottone, L Pagliaro
• Journal: The Italian journal of gastroenterology (Ital J Gastroenterol) 1991 Sep-Oct Vol. 23 Issue 7 Pg. 403-7 ISSN: 0392-0623 [Print] Italy
• PMID: 1742538 (Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)

Chemical References

• Rifamycins
• Neomycin
• Rifaximin

Topics

• Chronic Disease
• Female
• Hepatic Encephalopathy (drug therapy, physiopathology)
• Humans
• Male
• Middle Aged
• Neomycin (therapeutic use)
• Rifamycins (therapeutic use)
• Rifaximin